PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead

Key Takeaways

• Strategic focus on high-need gastroenterology segments and new indications aims to drive rapid adoption and expand long-term market potential.
  
• Extended product exclusivity and cost-optimization efforts are expected to sustain high-margin growth and accelerate the path to profitability.
  
• Heavy reliance on a single product and market, ongoing reimbursement challenges, finite exclusivity, and cost-cutting pressures threaten growth, profitability, and long-term sustainability.

Catalysts

A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

• Targeted focus on gastroenterologists is expected to drive higher-frequency prescribing, accelerating near-term adoption and revenue growth as sales resources are concentrated on the segment with highest unmet need and higher per-physician prescription rates.
  
• VOQUEZNA's exclusivity extended to at least 2033 reduces expected generic risk, supporting sustained high-margin revenue and earnings scalability over the medium/long term.
  
• The upcoming launch of the EoE Phase II trial and opportunity for additional indications (including potential pediatric exclusivity extension) positions Phathom to grow its addressable market and drive future top-line expansion.
  
• Secular growth in GI disease prevalence, as demonstrated by the large and expanding patient pool with unmet needs (30–40% of GERD patients remain symptomatic on PPIs), underpins durable long-term revenue potential.
  
• Cost-optimization initiatives, including the elimination of direct-to-consumer advertising and vendor spend reductions, are anticipated to speed progress toward profitability by lowering operating expenses and improving net margins.

Phathom Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Phathom Pharmaceuticals's revenue will grow by 56.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -76.8% today to 33.5% in 3 years time.
• Analysts expect earnings to reach $265.0 million (and earnings per share of $3.1) by about June 2029, up from -$157.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $551.7 million in earnings, and the most bearish expecting $142.7 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.7x on those 2029 earnings, up from -4.8x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 15.4x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

• Heavy dependence on a single product (VOQUEZNA) exposes Phathom to significant clinical, regulatory, or competitive risks-any negative developments related to vonoprazan, such as unfavorable trial results, new safety concerns, or a shift in physician/payer preferences, could substantially undermine future revenues and lead to prolonged periods of losses.
  
• Reliance on U.S. commercialization only and delayed ex-U.S. strategies means growth is tied to a single, increasingly scrutinized market; the lack of international diversification exposes the company to U.S.-specific payer restrictions, step edits, and potential regulatory or drug pricing headwinds, all of which can constrain addressable market and revenue growth.
  
• Persistent high gross-to-net discount rates (currently 55%–65%) and a significant portion of prescriptions filled as "cash pay" for Medicare patients signal ongoing reimbursement and formulary access challenges-these long-term dynamics can cap net sales, suppress net margins, and hinder scalability.
  
• The anticipated exclusivity for VOQUEZNA is finite (potentially ending in 2033), and there is a risk that subsequent patent challenges, earlier-than-expected generic competition, or slow progress in securing new indications or pediatric exclusivity could erode high-margin sales and compress future earnings sooner than projected.
  
• Ongoing need for aggressive cost-cutting-such as eliminating direct-to-consumer marketing, restructuring, and reduced third-party vendor spend-reflects pressure to reach profitability and maintain cash runway; if top-line growth lags or operational investments are further constrained, this can delay sustainability, limit pipeline development, and extend periods of negative free cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $23.7 for Phathom Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $13.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $792.0 million, earnings will come to $265.0 million, and it would be trading on a PE ratio of 10.7x, assuming you use a discount rate of 7.1%.
• Given the current share price of $9.59, the analyst price target of $23.7 is 59.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.